Search Results (39)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. | Academic Article |
Why?
|
| Brubaker, Lindsay | Person |
Why?
|
| Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. | Academic Article |
Why?
|
| Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. | Academic Article |
Why?
|
| Drug Disposition and Nephrotoxicity | Grant |
Why?
|
| Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. | Academic Article |
Why?
|
| The Notch signaling pathway as a mediator of tumor survival. | Academic Article |
Why?
|
| The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. | Academic Article |
Why?
|
| Camidge, David | Person |
Why?
|
| Afghahi, Anosheh | Person |
Why?
|
| Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer. | Academic Article |
Why?
|
| Alldredge, Jill | Person |
Why?
|
| Joy, Melanie | Person |
Why?
|
| Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. | Academic Article |
Why?
|
| ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. | Academic Article |
Why?
|